Humana (HUM) reported an adjusted loss of $0.70 per share for the third quarter. That beat the consensus estimate of a $1.03 loss by 17.6% and also cleared the Earnings Whisper number of -$0.85. Revenue rose 26.1% year over year to $41.155 billion, 1.7% above the $40.46 billion consensus. Management raised full-year adjusted EPS guidance to at least $9.50 from at least $9.00, a floor that had held since February.

The beat still needs context. Earnings fell 121.6% year over year, swinging from an adjusted profit of $3.24 a year ago to a loss. The Insurance segment posted an adjusted operating loss of $299 million versus a $270 million profit in 3Q25. Even the raised guidance implies a steep drop from 2025's $17.14 adjusted EPS, which management attributes to the Bonus Year 2026 Star Ratings headwind. The central tension is clear: Humana is beating a deliberately depressed bar in a reset year, while making a much stronger case that the reset is ending.

The quarter's underlying details were better than the headline loss suggests. The Insurance benefit ratio of 93.7% came in favorable to guidance of "slightly above 94 percent." The adjusted consolidated operating cost ratio improved to 11.2% from 11.8%. Investors should look past the GAAP figures. GAAP EPS of $1.33 was lifted by a $2.94-per-share put/call valuation gain tied to the CenterWell minority investments. The jump in GAAP guidance to at least $15.09 from $6.52 largely reflects the roughly $1.2 billion noncash reversal of the Welsh Carson put liability, partly offset by a $2.14 charge for the new BlackRock JV option. Neither figure says much about operating performance.

The conference call changed the tone more than the numbers did. Management said cost trend is running at the lower end of its 7-8% range, with inpatient and Part D favorability, an improvement from "in line" in the second quarter. Management also said it is ahead of plan on every Investor Day waterfall line item. The most consequential disclosure was Bonus Year 2028 Stars:

• a member-weighted rating of 4.17;
• roughly 95% of members in 4+ star plans;
• results well above the top-quartile target management had repeatedly described itself as "on track" for.

Early 2027 enrollment is also tracking ahead of expectations, with stronger recapture of roughly 600,000 plan-exit members and better new sales. Management now expects 2027 membership to grow, not hold flat or shrink. Medicaid added 104,000 members year to date, and CenterWell Senior Primary Care patients grew 30%.

The balance sheet story reinforces the improved setup. The BlackRock JV replaces the Welsh Carson structure, cuts GAAP debt-to-capital by about 130 basis points in the fourth quarter, and removes a 2027 put obligation previously sized at $1 billion to $1.5 billion. Separately, the roughly $900 million Gentiva stake sale is set to close in the fourth quarter. Management flagged potential dividend growth and higher buybacks as earnings recover, and a December 10 investor update will re-mark the 2028 targets.

Bears still have legitimate ammunition. Humana expects 2027 cost trend of 8-9%, up from 7-8% in 2026, with Part D trend accelerating to 14-15% from 11-12% because of new drugs. Management says this is priced into bids, but 2027 margin progress depends mainly on that pricing holding, and retention data is not yet known. The Stars tailwind is one-time and unquantified until late 2027. About 30% of it would flow to value-based providers, and the advantage could narrow as competitors improve. CenterWell's primary care earnings also declined year over year because of pressure in one Florida geography, which management said was mostly, but not fully, mitigated.

The market had already priced in much of the recovery. Shares closed at $411.79 before the report, up 6.1% from the open after the July release and 32.4% above the 200-day moving average. However, the stock was 9.8% below the 52-week high of $456.50 set on October 9 during this inter-earnings period, meaning some of the run-up had already faded. Investor sentiment edged from slightly positive to slightly negative, roughly neutral overall, so expectations were not euphoric heading into the print.

The bottom line is that Humana delivered a cleaner quarter than its headline loss and 121.6% earnings decline imply. Favorable benefit and cost ratios, a higher guidance floor, standout Stars results, and a de-risked balance sheet suggest the company is moving from repair toward recovery. The debate now shifts to 2027: whether pricing can absorb a hotter cost trend, how much of the Stars windfall actually reaches earnings, and whether December's update converts "ahead of plan" into numbers.